Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide1 and ghrelin in obese patients with Type 2 diabetes mellitus

Diabetic Medicine

Volumn 29, Issue 8, 2012, Pages

  Thondam, S K ^a   Cross, A ^a   Cuthbertson, D J ^a   Wilding, J P ^a   Daousi, C ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

Dipeptidyl peptidase 4; Ghrelin; Glucagon like peptide1; Incretin hormones; Metformin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GHRELIN; GLUCAGON LIKE PEPTIDE 1; METFORMIN;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HUMAN; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSERVATIONAL STUDY; PROSPECTIVE STUDY;

AREA UNDER CURVE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; FEMALE; GHRELIN; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; OBESITY; POSTPRANDIAL PERIOD; PROSPECTIVE STUDIES;

EID: 84863998110     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2012.03675.x     Document Type: Article

References (26)

1. Bailey CJ, Wilcock C, Day C. Effect of metformin on glucose metabolism in the splanchnic bed. Br J Pharmacol 1992; 105: 1009-1013.
2. Penicaud L, Hitier Y, Ferre P, Girard J. Hypoglycaemic effect of metformin in genetically obese (fa/fa) rats results from an increased utilization of blood glucose by intestine. Biochem J 1989; 262: 881-885.
3. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 550-554.
4. Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Saeki T et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 2002; 298: 779-784.
5. Lugari R, Dell'Anna C, Sarti L, Gnudi A. Effects of metformin on intestinal and pancreatic endocrine secretion in type2 (non-insulin-dependent) diabetes. In: Belfiore F, ed. Molecular and Cell Biology of Type2 Diabetes and its Complications. Switzerland: Karger Publishers, 1998: 14: 161-163.
6. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001; 24: 489-494.
7. Mannucci E, Tesi F, Bardini G, Ognibene A, Petracca MG, Ciani S et al. Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type2 diabetes. Diabetes Nutr Metab 2004; 17: 336-342.
8. Cuthbertson J, Patterson S, O'Harte FPM, Bell PM. Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type2 diabetes. Diabet Med 2009; 26: 649-654.
9. Lindsay JR, Duffy NA, McKillop AM, Ardill J, O'Harte FPM, Flatt PR et al. Inhibition of dipeptidyl peptidaseIV activity by oral metformin in Type2 diabetes. Diabet Med 2005; 22: 654-657.
10. Turner R. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type2 diabetes (UKPDS34). Lancet 1998; 352: 854-865.
11. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with typeII non-insulin-dependent diabetes. Obes Res 1998; 6: 47-53.
12. Paolisso G, Amato L, Eccellente R, Gambardella A, Tagliamonte MR, Varricchio G et al. Effect of metformin on food intake in obese subjects. Eur J Clin Invest 1998; 28: 441-446.
13. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194-198.
14. Doogue MP, Begg EJ, Moore MP, Lunt H, Pemberton CJ, Zhang M. Metformin increases plasma ghrelin in Type2 diabetes. Br J Clin Pharmacol 2009; 68: 875-882.
15. English PJ, Ashcroft A, Patterson M, Dovey TM, Halford JCG, Harrison J et al. Metformin prolongs the postprandial fall in plasma ghrelin concentrations in type2 diabetes. Diabetes Metab Res Rev 2007; 23: 299-303.
16. Kusaka I, Nagasaka S, Horie H, Ishibashi S. Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type2 diabetic patients: a possible role in weight stability? Diabetes Obes Metab 2008; 10: 1039-1046.
17. Schöfl C, Horn R, Schill T, Schlösser HW, Müller MJ, Brabant G. Circulating ghrelin levels in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 4607-4610.
18. Cuthbertson J, Patterson S, O'Harte FP, Bell PM. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type2 diabetes mellitus. Metab Clin Exp 2011; 60: 52-56.
19. Hinke SA, Kühn-Wache K, Hoffmann T, Pederson RA, McIntosh CHS, Demuth HU. Metformin effects on dipeptidylpeptidaseIV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 2002; 291: 1302-1308.
20. Migoya EM, Bergeron R, Miller JL, Snyder RNK, Tanen M, Hilliard D et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010; 88: 801-808.
21. Maida A, Lamont BJ, Cao X, Drucker DJ. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia 2011; 54: 339-349.
22. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005; 48: 612-615.
23. Nauck MA, El-Ouaghlidi A. The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Diabetologia 2005; 48: 608-611.
24. Ahrén B, Foley JE, Bosi E. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 2011; 13: 193-203.
25. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type2 diabetes. Lancet 2006; 368: 1696-1705.
26. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide1 in type2 diabetic patients. Diabetes 2001; 50: 609-613.